Payment overview · 2025
General Payments
$525.03
26 reported records · 12 companies
Healthcare provider profile · identity verified
Azzam A Adhal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PANAMA CITY, FL · NPI 1295714129
Verified facts
What the public records show
CMS Open Payments records show Azzam A Adhal, MD received $525.03 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.52 | 19.5% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $74.02 | 14.1% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.80 | 11.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.76 | 9.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.37 | 8.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.79 | 7.6% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.47 | 7.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.80 | 7.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.96 | 4.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.97 | 4.2% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.70 | 3.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.87 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $525.03 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $113.81 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.10 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $66.10 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $61.80 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.76 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.76 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $44.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.80 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 86 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 755 | 232 |
| Losartan Potassium | Losartan Potassium | 566 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 541 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 515 | 171 |
| Carvedilol | Carvedilol | 447 | 130 |
| Omeprazole | Omeprazole | 418 | 123 |
| Gabapentin | Gabapentin | 411 | 123 |
| Furosemide | Furosemide | 374 | 105 |
| Metformin Hcl | Metformin Hcl | 358 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 311 | 107 |
| Lisinopril | Lisinopril | 256 | 87 |
| Eliquis | Apixaban | 254 | 64 |
| Clopidogrel | Clopidogrel Bisulfate | 244 | 84 |
| Azithromycin | Azithromycin | 227 | 159 |
| Alprazolam | Alprazolam | 204 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 69 |
| Simvastatin | Simvastatin | 189 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 84 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 58 |
| Montelukast Sodium | Montelukast Sodium | 160 | 50 |
| Methylprednisolone | Methylprednisolone | 154 | 110 |
| Mounjaro | Tirzepatide | 145 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 49 |
| Famotidine | Famotidine | 141 | 49 |
| Allopurinol | Allopurinol | 138 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 134 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 44 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 46 |
| Ezetimibe | Ezetimibe | 120 | 40 |
| Clonidine Hcl | Clonidine Hcl | 119 | 43 |
| Doxazosin Mesylate | Doxazosin Mesylate | 119 | 39 |
| Potassium Chloride | Potassium Chloride | 119 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 41 |
| Cefdinir | Cefdinir | 112 | 86 |
| Sertraline Hcl | Sertraline Hcl | 110 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 33 |
| Bupropion Xl | Bupropion Hcl | 102 | 15 |
| Meloxicam | Meloxicam | 102 | 33 |
| Trazodone Hcl | Trazodone Hcl | 98 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 34 |
| Januvia | Sitagliptin Phosphate | 93 | 17 |
| Farxiga | Dapagliflozin Propanediol | 86 | 20 |
| Sucralfate | Sucralfate | 84 | 28 |
| Buspirone Hcl | Buspirone Hcl | 83 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 30 |
| Nitroglycerin | Nitroglycerin | 77 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 27 |
| Cefuroxime | Cefuroxime Axetil | 75 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 16 |
| Ozempic | Semaglutide | 68 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 66 | 23 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 65 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 17 |
| Glipizide | Glipizide | 65 | 20 |
| Alendronate Sodium | Alendronate Sodium | 64 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 60 | 25 |
| Clonazepam | Clonazepam | 59 | 12 |
| Spironolactone | Spironolactone | 58 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 21 |
| Tramadol Hcl | Tramadol Hcl | 56 | 28 |
| Digoxin | Digoxin | 54 | 13 |
| Levetiracetam | Levetiracetam | 54 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 17 |
| Baclofen | Baclofen | 52 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 22 |
| Levofloxacin | Levofloxacin | 52 | 40 |
| Methocarbamol | Methocarbamol | 52 | 24 |
| Fluconazole | Fluconazole | 51 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 51 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 42 |
| Jardiance | Empagliflozin | 48 | 14 |
| Estradiol | Estradiol | 47 | 14 |
| Pregabalin | Pregabalin | 47 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 31 |
| Donepezil Hcl | Donepezil Hcl | 43 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 14 |
| Myrbetriq | Mirabegron | 43 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 17 |
| Lorazepam | Lorazepam | 41 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | 18 |
| Novolog Flexpen | Insulin Aspart | 40 | 16 |
| Xarelto | Rivaroxaban | 40 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 39 | 15 |
| Atenolol | Atenolol | 38 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 22 |
| Prednisone | Prednisone | 36 | 15 |
| Finasteride | Finasteride | 35 | 13 |
| Temazepam | Temazepam | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 20 |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Eszopiclone | Eszopiclone | 31 | 15 |
| Ketoconazole | Ketoconazole | 31 | 11 |
| Meclizine Hcl | Meclizine Hcl | 31 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 30 | 20 |
| Linzess | Linaclotide | 29 | suppressed |
| Nystatin | Nystatin | 29 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 21 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 23 |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 20 |
| Midodrine Hcl | Midodrine Hcl | 22 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | 11 |
| Topiramate | Topiramate | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 15 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $525.03 · 26 records | Novo Nordisk Inc | CAPVAXIVE, Cologuard Collection Kit, FANAPT, FARXIGA, JARDIANCE, Kerendia, Leqembi, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error